- SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation. [Journal Article]Ann Oncol. 2026 Aug 06. [Online ahead of print]AO
- CONCLUSIONS: The primary endpoint of the SKYSCRAPER-03 study was not met. Tiragolumab plus atezolizumab was tolerated but did not offer additional benefit over durvalumab.
- Publisher Full Text (DOI)
- Towards the practical use of AI: a tool for scalable colorectal cancer screening. [Editorial]Ann Oncol. 2026 Aug; 37(8):1024-1027.AO
- Publisher Full Text (DOI)
- Reply to Next-Generation Sequencing Consensus Guidelines for Sarcoma: Progress, Gaps, and the Path Forward. [Letter]Ann Oncol. 2026 Jul 27. [Online ahead of print]AO
- Publisher Full Text (DOI)
- A Multimodal Deep Learning Model for Preoperative Prediction of Postoperative Complications in Gastric Cancer. [Journal Article]Ann Oncol. 2026 Jul 16. [Online ahead of print]AO
- CONCLUSIONS: DeepComp showed consistent performance across validation cohorts for preoperative risk stratification of postoperative complications and long-term survival, and may support individualized perioperative management.
- Publisher Full Text (DOI)
- Keeping the story, turning the page: from prognostic to predictive AI in high-risk prostate cancer. [Editorial]Ann Oncol. 2026 Jul 10. [Online ahead of print]AO
- Publisher Full Text (DOI)
- Measurement of ovarian reserve to tailor systemic therapy decisions: future potential or ready for primetime? [Editorial]Ann Oncol. 2026 Jul 09. [Online ahead of print]AO
- Publisher Full Text (DOI)
- HER2-directed TAC T cells in solid tumors: a step forward, but not yet a therapeutic leap. [Editorial]Ann Oncol. 2026 Jul 07. [Online ahead of print]AO
- Publisher Full Text (DOI)
- The ethical obligation to use positive trial results. [Letter]Ann Oncol. 2026 Jun 27. [Online ahead of print]AO
- Publisher Full Text (DOI)
- Lorlatinib: the crown jewel of ALK inhibitors. [Editorial]Ann Oncol. 2026 Jun 26. [Online ahead of print]AO
- Publisher Full Text (DOI)
- TROP2-directed antibody-drug conjugates: new first-line treatment for all patients with advanced triple-negative breast cancer? [Editorial]Ann Oncol. 2026 Aug; 37(8):1015-1020.AO
- Publisher Full Text (DOI)
- When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology. [Editorial]Ann Oncol. 2026 Jul; 37(7):886-888.AO
- Publisher Full Text (DOI)
- PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block? [Editorial]Ann Oncol. 2026 Jul; 37(7):877-879.AO
- Publisher Full Text (DOI)
- Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic. [Editorial]Ann Oncol. 2026 Jul; 37(7):873-876.AO
- Publisher Full Text (DOI)
- Next-generation sequencing consensus guidelines for sarcoma: progress, gaps, and the path forward. [Editorial]Ann Oncol. 2026 Jun 24. [Online ahead of print]AO
- Publisher Full Text (DOI)
- SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer. [Journal Article]Ann Oncol. 2026 Jun 20. [Online ahead of print]AO
- CONCLUSIONS: Addition of pembrolizumab to SG did not significantly improve outcomes in HR-positive/HER2-negative MBC unselected by PD-L1. In the PD-L1-positive population, the trend in PFS and OS favoring SG plus pembrolizumab warrants further investigation in larger randomized trials.
- Publisher Full Text (DOI)